Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt

NCT01452347 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT01452347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01452347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2011
Completion date
June 30, 2013
Enrollment
328 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

heart valve diseases